Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + penpulimab first-line treatment for advanced PPGL
ChiCTR2400083008Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Apr 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and penpulimab in pheochromocytoma and Paraganglioma (PGL), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective response rate. Started Apr 2024; status: recruiting.
02
Drugs
anlotinibpenpulimab
03
Conditions
pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on ChiCTR2400083008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083008.